In the long effort to tame a disease that quietly deposits protein in the heart until the muscle can no longer bear its own weight, a large clinical trial has returned a verdict that is neither defeat nor triumph. Eplontersen, tested in 1,432 patients with transthyretin-mediated amyloid cardiomyopathy over nearly three years, could not reduce cardiovascular deaths or major cardiac events — the measures medicine uses to count survival — yet patients who received it felt meaningfully better and walked measurably farther than those who did not. Presented in Phoenix in October 2026, the findings a
Eplontersen Misses Primary Endpoint but Improves Quality of Life in ATTR-CM
No direct casualties or displacement; however, 1,432 patients with serious heart condition (ATTR-CM) were studied, with treatment showing mixed efficacy outcomes.
Preserved function, but not mortality—the drug's paradox
Mark
So the drug didn't work. It failed the primary endpoint. Why is this being presented as a win?
Mimi
It didn't work for what it was designed to do—prevent death and major cardiac events. But the secondary outcomes showed real improvements in how patients felt and what they could do physically. That matters to people living with this disease.
Luke
But we need to be careful here. The primary endpoint missed with a confidence interval that crossed 1.0. That's not a borderline miss—that's a clear miss. The secondary endpoints did show statistical significance, but secondary endpoints are hypothesis-generating, not confirmatory. They weren't the main question the trial was built to answer.
Mark
So what does this mean for patients? Can they take this drug or not?
Mimi
That's the real question. The drug appears to slow the decline in quality of life and physical function over nearly three years. For someone with ATTR-CM, that could mean staying mobile, staying independent longer. But it won't prevent a heart attack or sudden death.
Luke
And we should note that the benefits were largest in patients not already on a TTR stabilizer. That's a subgroup finding, and subgroup findings need to be interpreted cautiously. We don't know if that's a real biological difference or just noise in the data.
Mark
How many patients are we talking about here?
Mimi
The trial enrolled 1,432 patients—715 on eplontersen, 717 on placebo. Mean age was 76 years, mostly men, mostly wild-type ATTR-CM. So this is a fairly large, representative population.
Luke
And the follow-up was solid—140 weeks, nearly three years. That's long enough to see real effects. But the fact that cardiovascular mortality was nearly identical between groups—74 deaths versus 70—tells you the drug isn't changing the fundamental disease trajectory.
Mark
So where does this leave eplontersen?
Mimi
In a gray zone. It's not a mortality-reducing drug. But if you're a patient who values maintaining your ability to walk and your quality of life, it might be worth considering. Particularly if you're not already on another TTR-targeting therapy.
Luke
The key unknown is how this compares to other treatments already available. There are TTR stabilizers and other TTR silencers on the market. We don't have head-to-head data. We only know eplontersen versus placebo. That's important context that's missing from the conversation.
Il Polso
- A drug designed to silence the protein that destroys the heart in ATTR-CM failed its central test — it could not reduce deaths or serious cardiac events compared to placebo over 140 weeks.
- The margin of failure was narrow but statistically clear: 381 events in the treatment group versus 392 in placebo, a difference so small it could have occurred by chance, with cardiovascular deaths nearly identical between arms.
- Beneath that headline, patients on eplontersen reported significantly less deterioration in daily life and emotional well-being, and preserved their walking capacity nearly 20 meters better than those on placebo — gaps that are both statistically significant and clinically felt.
- The benefit appeared strongest in patients not already taking a TTR stabilizer, raising the possibility that eplontersen works best alone rather than layered onto existing therapies.
- Medicine is now left to weigh a drug that cannot extend life but may extend the quality of it — a distinction that will force physicians, patients, and health systems into difficult, deeply personal conversations about what treatment is for.
In the long effort to tame a disease that quietly deposits protein in the heart until the muscle can no longer bear its own weight, a large clinical trial has returned a verdict that is neither defeat nor triumph. Eplontersen, tested in 1,432 patients with transthyretin-mediated amyloid cardiomyopathy over nearly three years, could not reduce cardiovascular deaths or major cardiac events — the measures medicine uses to count survival — yet patients who received it felt meaningfully better and walked measurably farther than those who did not. Presented in Phoenix in October 2026, the findings ask an old question in a new form: when a disease cannot be stopped, what does it mean to help someone live with it?
A clinical trial built to determine whether eplontersen could protect the hearts of patients with a rare and destructive protein-deposit disease has delivered a complicated answer. The CARDIO-TTRansform trial, which followed 1,432 patients over nearly three years, found that the drug — a subcutaneous injection given monthly — did not reduce cardiovascular deaths or serious heart-related events compared to placebo. The difference in outcomes was too small to rule out chance, and deaths from cardiac causes were nearly identical between the two groups.
The patients enrolled were predominantly older men, most in their mid-seventies, the majority living with the wild-type form of ATTR-CM — a condition in which abnormal transthyretin protein accumulates in the heart muscle without any inherited genetic cause. Their heart walls were measurably thickened, and their symptoms ranged from mild to moderate heart failure. It was a representative and seriously ill population, which made the primary failure all the more consequential.
Yet the secondary findings complicated that verdict. Patients on eplontersen experienced a 5.4-point decline in their Kansas City Cardiomyopathy Questionnaire scores — a measure of how disease affects daily life and well-being — compared to a 9.4-point decline in the placebo group. On the six-minute walk test, those taking the drug lost roughly 27 meters of walking capacity by study's end, while placebo patients lost nearly 47. Both differences were statistically significant and, for people living with a progressive disease, potentially meaningful.
Dr. Brett Sperry, who presented the results at the Heart Failure Society of America's annual meeting in Phoenix, argued that preserving how patients feel and function carries real value in a disease that steadily erodes independence. He noted that the benefit was most pronounced in patients who were not already on a TTR stabilizer, suggesting eplontersen may be most effective as a standalone therapy rather than an addition to existing treatment.
The trial leaves the medical community with a drug that occupies unfamiliar ground — one that cannot extend survival but may slow the loss of the things that make survival worthwhile. Whether that is enough to justify regular injections, and how it fits alongside other available therapies, is a question that will now move from trial data into the examining room, where physicians and patients must decide together what they are trying to preserve.
A large clinical trial of eplontersen, a drug designed to treat a rare and serious form of heart disease, fell short of its primary goal but revealed an unexpected benefit: patients who took the medication felt better and could walk farther than those on placebo. The findings, presented at the Heart Failure Society of America's annual meeting in Phoenix in October 2026, complicate the picture of what the drug can actually do for people living with transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, a condition in which abnormal protein deposits damage the heart muscle.
The CARDIO-TTRansform trial enrolled 1,432 patients across the globe and randomly assigned them to receive either eplontersen, a subcutaneous injection given once every four weeks, or placebo. The study was designed to test whether the drug could reduce cardiovascular deaths and serious heart-related events over nearly three years. Participants had a mean age of 76.4 years, and roughly 91 percent were men. Most had wild-type ATTR-CM, a form of the disease that develops without an inherited genetic mutation. The researchers confirmed amyloid deposits in the heart using Congo Red staining or technetium imaging, and all participants had measurable thickening of the heart wall and heart failure symptoms ranging from mild to moderate.
By the end of the 140-week study period, the drug did not achieve what it was primarily designed to do. A total of 210 patients in the eplontersen group experienced 381 cardiovascular events—including deaths and hospitalizations—compared to 231 patients in the placebo group who experienced 392 events. The rate ratio of 0.89, with a confidence interval spanning from 0.73 to 1.09, meant the difference could easily have occurred by chance. Cardiovascular deaths occurred in 74 patients receiving eplontersen and 70 receiving placebo, a distinction too small to be meaningful. The drug had failed to demonstrate that it could extend life or prevent major cardiac crises.
Yet the secondary measures told a different story. Patients taking eplontersen showed smaller declines in their Kansas City Cardiomyopathy Questionnaire scores, a validated tool that measures how heart disease affects daily life, symptoms, and emotional well-being. Those on the drug saw their scores drop by 5.4 points compared to a 9.4-point decline in the placebo group—a difference of 4 points that was statistically significant and clinically meaningful. Similarly, on the six-minute walk test, a standard measure of exercise capacity, patients on eplontersen walked 27.5 meters less at the end of the study, while those on placebo walked 47.3 meters less. The 19.7-meter difference in preservation of walking distance was also statistically significant.
Dr. Brett Sperry, who presented the findings and serves as co-director of cardiovascular imaging at Saint Luke's Health System, framed the results as evidence that eplontersen could help patients maintain their quality of life and physical function, even if it could not prevent death or major cardiac events. He noted that the treatment landscape for ATTR-CM has shifted dramatically in recent years, with drugs that stabilize or silence the transthyretin protein now available, yet substantial gaps remain. Patients still struggle with symptoms, physical limitations, and the erosion of their ability to do the things that matter to them. Sperry emphasized that eplontersen appeared to preserve health status, with the largest benefits seen in patients who were not already taking a TTR stabilizer at baseline—suggesting the drug might work best as a single therapy rather than in combination with other treatments.
The results present a clinical puzzle. A drug that cannot prevent death or major cardiac events but does slow the decline in how patients feel and function occupies an unusual space in modern medicine. It is not a life-saver in the traditional sense, yet it may offer something that matters deeply to people living with a progressive disease: the chance to maintain their independence, their mobility, and their sense of well-being for a longer period. Whether that benefit justifies the cost and burden of regular injections, and how it compares to other available treatments, remains a question for physicians and patients to work through together. The trial enrolled a large, representative population and ran for nearly three years, lending weight to its findings. But the gap between what eplontersen can and cannot do—between preserving function and extending life—will likely shape how the drug is used and whether it becomes a standard part of ATTR-CM care.
Citazioni salienti
Eplontersen preserved health status compared with placebo, with the largest benefits in those not on a baseline stabilizer, and the treatment effects were consistent across subgroups and domains.— Dr. Brett Sperry, Saint Luke's Health System, presenting at HFSA 2026
There's a large unmet need that remains, not only in mortality and hospitalizations, but in health status—how patients feel, their symptoms, their physical and social function and limitations, and their quality of life.— Dr. Brett Sperry
Vuoi la storia completa?
Leggi l'originale su HCPLive ↗
Health & Medicine